NASDAQ:IFRX - Nasdaq - NL0012661870 - Common Stock - Currency: USD
NASDAQ:IFRX (6/18/2025, 11:11:11 AM)
0.8099
+0.04 (+5.18%)
The current stock price of IFRX is 0.8099 USD. In the past month the price decreased by -56.5%. In the past year, price decreased by -50.01%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.12 | 328.79B | ||
AMGN | AMGEN INC | 13.96 | 155.81B | ||
GILD | GILEAD SCIENCES INC | 13.98 | 134.60B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.76B | ||
REGN | REGENERON PHARMACEUTICALS | 11.64 | 55.67B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 41.17B | ||
ARGX | ARGENX SE - ADR | 94.63 | 33.22B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.56 | 27.72B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.21B | ||
NTRA | NATERA INC | N/A | 23.17B | ||
BIIB | BIOGEN INC | 8.05 | 18.67B | ||
INSM | INSMED INC | N/A | 18.35B |
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. The company is headquartered in Jena, Thueringen and currently employs 74 full-time employees. The company went IPO on 2017-11-16. The firm's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The firm's product pipeline also includes IFX-2, which is in preclinical development.
INFLARX NV
Winzerlaer Str. 2
Jena THUERINGEN 07745 DE
CEO: Niels Riedemann
Employees: 74
Phone: 493641508180
The current stock price of IFRX is 0.8099 USD. The price increased by 5.18% in the last trading session.
The exchange symbol of INFLARX NV is IFRX and it is listed on the Nasdaq exchange.
IFRX stock is listed on the Nasdaq exchange.
14 analysts have analysed IFRX and the average price target is 5.39 USD. This implies a price increase of 565.69% is expected in the next year compared to the current price of 0.8099. Check the INFLARX NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.
INFLARX NV (IFRX) has a market capitalization of 54.37M USD. This makes IFRX a Micro Cap stock.
INFLARX NV (IFRX) currently has 74 employees.
INFLARX NV (IFRX) has a resistance level at 1.85. Check the full technical report for a detailed analysis of IFRX support and resistance levels.
The Revenue of INFLARX NV (IFRX) is expected to decline by -45.24% in the next year. Check the estimates tab for more information on the IFRX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
IFRX does not pay a dividend.
INFLARX NV (IFRX) will report earnings on 2025-08-06, before the market open.
INFLARX NV (IFRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.87).
The outstanding short interest for INFLARX NV (IFRX) is 2.02% of its float. Check the ownership tab for more information on the IFRX short interest.
ChartMill assigns a fundamental rating of 2 / 10 to IFRX. IFRX may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months IFRX reported a non-GAAP Earnings per Share(EPS) of -0.87. The EPS decreased by -5.63% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -51.4% | ||
ROE | -63.47% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 84% to IFRX. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of 0.37% and a revenue growth -45.24% for IFRX